Xanthine oxidase-IN-18
Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC50 = 0.263 μM). Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511)-induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C23H25N3O5
- Peso molecular:423.46
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Xanthine oxidase-IN-18 (MT7) exhibits no cytotoxicity in L929 mouse fibroblast cells at concentrations up to 100 μM[1].
Xanthine oxidase-IN-18 suppresses the growth of MDA-MB-231 breast cancer cells (IC50 = 1.24 μM) approximately 2-fold more potently than that in A549 lung cancer cells (IC50 = 3.04 μM), confirming intracellular XO inhibition[1].
Xanthine oxidase-IN-18 (1-10 μM, 24 h) demonstrates significant, concentration-dependent ROS scavenging activity in RAW 264.7 macrophages[1].
Xanthine oxidase-IN-18 (48 h) markedly reduces the activity of antioxidant enzymes, inhibiting superoxide dismutase (SOD) by 66%, glutathione reductase (GR) by 49%, and the H2O2 detoxifying enzyme by 38%[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 macrophages
-
Concentration:1, 5 and 10 μM
-
Incubation Time:24 h
-
Result:Showed no significant reduction in cell viability at any tested concentration.
Xanthine oxidase-IN-18 (5, 50 and 300 mg/kg, i.g., single dose) demonstrates no mortality and no observed toxicity in an acute oral toxicity study in SD rats[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SD Rats (202 ± 20 g) intraperitoneally injected with Potassium oxonate (300 mg/kg)[1]
-
Dosage:10, 20 and 40 mg/kg
-
Administration:i.g., single dose 1 h after Potassium oxonate
-
Result:Showed a significant reduction in serum uric acid compared with the model group after 2 h.
Exhibited a dose-dependent decrease in uric acid levels.
Showed comparable anti-hyperuricemia effects at 40 mg/kg to Febuxostat (HY-14268).
Did not cause any significant changes in creatinine or urea nitrogen levels in rats.
Did not produce any harmful effects on the liver or kidneys.
-
Animal Model:SD Rats (202 ± 20 g)[1]
-
Dosage:5, 50 and 300 mg/kg
-
Administration:p.o, single dose
-
Result:None of rats died during the experiment, indicating that it was safe at the dose level of 300 mg/kg.
Exhibited no signs of toxicity in major organs after 14 days in the 300 mg/kg group.
Chemical Information
-
Peso molecular 423.46
-
Fòrmula C23H25N3O5
-
SMILES
C/C=C/C1=CC=C(OCC2=CN(CCCOC3=CC=C(OCO4)C4=C3)N=N2)C(OC)=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Xanthine oxidase-IN-18 Related Classifications
HY-178342 Related Classifications
Powered by Bioz